X

Trial Profile

A Phase I/II Study of Isatuximab (Anti-CD38 mAb) Administered as a Single Agent in Japanese Patients With Relapsed and Refractory Multiple Myeloma

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 03 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Isatuximab (Primary)
Indications Multiple myeloma
Focus Adverse reactions; Therapeutic Use
Acronyms Islands
Sponsors Sanofi

Most Recent Events

01 Aug 2023 Results of prespecified second analysis conducted 20 months after the first dosing of the last participant, published in the Hematological Oncology.
22 Nov 2022 Status changed from active, no longer recruiting to completed.
19 Sep 2022 Planned End Date changed from 11 Oct 2022 to 10 Oct 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com